Off-label use of "smart drugs" — pharmaceuticals meant to treat disorders, such as attention deficit hyperactivity disorder, narcolepsy and Alzheimer's disease — are becoming increasingly popular among college students hoping to get ahead. The drugs are often used because they improve focus and alertness for longer periods of time. But is this cheating? Should their use as cognitive enhancers be approved by the Food and Drug Administration, the medical community and society? Do the benefits outweigh the risks?

There's not widespread agreement, and various experts have various points of view. This "2-Minute Debate" is part of a series co-produced by Intelligence Squared U.S. and Newsy.

The panel:

Dr. Anjan Chatterjee, professor at University of Pennsylvania and chair of neurology at Pennsylvania Hospital

Nita Farahany, professor at Duke University and director of Duke Science & Society

Eric Racine, director of the Neuroethics Research Unit at IRCM

Nicole Vincent, associate professor of philosophy, law and neuroscience at Georgia State University

Watch the full debate at Intelligence Squared U.S.

About the Author

Keep Reading

Collect candy, play carnival games for prizes and do more not-so-scary stuff at Boo at the Zoo at Zoo Atlanta on Saturday and Sunday. (Courtesy of Zoo Atlanta)

Credit: Photo courtesy of Zoo Atlanta

Featured

Coca-Cola plans to sell a majority stake in Africa’s largest Coca-Cola bottler. (AJC FILE)